Rachel Swansburg 10/18/25 Rachel Swansburg 10/18/25 GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025. Read More Rachel Swansburg 4/28/25 Rachel Swansburg 4/28/25 CLSP-1025, a first-in-class precision T-cell engager for the treatment of p53 mutant cancers Read More Rachel Swansburg 11/7/24 Rachel Swansburg 11/7/24 CLSP-1025, a novel bispecific T-cell engager targeting the p53R175H mutant peptide presented by HLA-A*02:01 Read More
Rachel Swansburg 10/18/25 Rachel Swansburg 10/18/25 GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025. Read More
Rachel Swansburg 4/28/25 Rachel Swansburg 4/28/25 CLSP-1025, a first-in-class precision T-cell engager for the treatment of p53 mutant cancers Read More
Rachel Swansburg 11/7/24 Rachel Swansburg 11/7/24 CLSP-1025, a novel bispecific T-cell engager targeting the p53R175H mutant peptide presented by HLA-A*02:01 Read More
